Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 16, 2024VaccineOpen Access

Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKatie SteenackersNHNikita HanningLBLiesbeth Bruckers

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Steenackers et al. (2024) studied this question.

synapsesocial.com/papers/68e6023bb6db6435875959a3https://doi.org/10.1016/j.vaccine.2024.07.018
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice2024 · 1 citations
  2. 2Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination2024 · 2 citations
  3. 3Longevity and Magnitude of Antibody Responses After Homologous and Heterologous COVID-19 Booster Vaccinations in Bangladesh2026
  4. 4Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults ≥ 50 years: a prospective, observational cohort study2024 · 2 citations
  5. 5Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study2024 · 3 citations